Companion Diagnostics: World Market Outlook 2011-2021
Our latest pharma report - Companion Diagnostics: World Market Outlook 2011-2021 - offers a comprehensive view of the global companion diagnostics market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the companion diagnostics market in 2011 to be worth $1.57bn. A number of specialty drugs will be associated with a companion diagnostic test by 2021, increasing the global market for companion diagnostics.
Companion diagnostics are diagnostic tests that are linked to a particular drug/therapy. This is a small, emerging market at present, but one of the fastest growing segments in the IVD market. The concept of a drug-diagnostic combination is not new, but has only started to garner interest, with the move of healthcare towards personalised medicine. Companion diagnostics combined with targeted therapeutics are the tools for providing personalised treatment. This market has significant potential for growth with the increasing demand for safer, efficacious drugs.
Visiongain's research suggests that the world companion diagnostics market will benefit from developments in biomarker discovery and use in early stages of drug development. These biomarkers for disease can be developed into companion diagnostics for clinical use. Also benefiting the companion diagnostics market will be efforts on the part of the regulatory authorities to develop clearer regulatory guidelines for the co-development of companion diagnostics.
The Companion Diagnostics: World Market Outlook 2011-2021 report examines the scope of growth available in the companion diagnostics industry given the increasing cost of drug development, rising cost of healthcare, and the need for medicines which do not have adverse drug reactions.
The companion diagnostics market is the fastest growing segment in the IVD market. Visiongain predicts that this market will grow steadily to 2021. The future of the companion diagnostics market appears promising, with increases in the demand for high priced specialist therapies and the demand for safer, more-efficacious drugs.
How will the companion diagnostic market develop this decade? Which regions offer the most significant growth opportunities between 2011 and 2021? Which of the companion diagnostic submarkets are growing most strongly? Who are the leading companies in the companion diagnostics market? Which regions offer the most significant companion diagnostics market growth opportunities between 2011 and 2021?
Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.
Detailed analysis of the global Companion Diagnostics Market
Companion Diagnostics: World Market Outlook 2011-2021 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 50 tables and figures included, as well as two full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Why you should buy Companion Diagnostics: World Market Outlook 2011-2021
In this report, you will receive the following benefits in particular:
Companion diagnostics are diagnostic tests that are linked to a particular drug/therapy. This is a small, emerging market at present, but one of the fastest growing segments in the IVD market. The concept of a drug-diagnostic combination is not new, but has only started to garner interest, with the move of healthcare towards personalised medicine. Companion diagnostics combined with targeted therapeutics are the tools for providing personalised treatment. This market has significant potential for growth with the increasing demand for safer, efficacious drugs.
Visiongain's research suggests that the world companion diagnostics market will benefit from developments in biomarker discovery and use in early stages of drug development. These biomarkers for disease can be developed into companion diagnostics for clinical use. Also benefiting the companion diagnostics market will be efforts on the part of the regulatory authorities to develop clearer regulatory guidelines for the co-development of companion diagnostics.
The Companion Diagnostics: World Market Outlook 2011-2021 report examines the scope of growth available in the companion diagnostics industry given the increasing cost of drug development, rising cost of healthcare, and the need for medicines which do not have adverse drug reactions.
The companion diagnostics market is the fastest growing segment in the IVD market. Visiongain predicts that this market will grow steadily to 2021. The future of the companion diagnostics market appears promising, with increases in the demand for high priced specialist therapies and the demand for safer, more-efficacious drugs.
How will the companion diagnostic market develop this decade? Which regions offer the most significant growth opportunities between 2011 and 2021? Which of the companion diagnostic submarkets are growing most strongly? Who are the leading companies in the companion diagnostics market? Which regions offer the most significant companion diagnostics market growth opportunities between 2011 and 2021?
Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.
Detailed analysis of the global Companion Diagnostics Market
Companion Diagnostics: World Market Outlook 2011-2021 examines that sector critically, through a comprehensive review of information sources, both primary and secondary. This report provides detailed sales forecasts, market share analyses, discussions of pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 50 tables and figures included, as well as two full interviews with relevant authorities. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Why you should buy Companion Diagnostics: World Market Outlook 2011-2021
In this report, you will receive the following benefits in particular:
- You will receive our assessment of the current market for companion diagnostics
- You will discover sales trends for the overall companion diagnostics market from 2011 to 2021 - seeing where commercial growth will occur
- You will discover sales trends for the main segment - theranostics - from 2011 to 2021 - with detailed discussions of market potential
- You will receive sales forecasts for leading geographical markets (US, Japan, Germany, France, Italy, Spain, UK, China and India), with informed discussion
- You will assess leading companies in the companion diagnostics market, providing products and services in the market
- You will see a compiled list of some theranostic kits and lab tests that are currently available in the market, and drug-diagnostic combinations in development by pharmaceutical and diagnostic companies
- You will examine the emerging business models for the development of companion diagnostics
- You will be able to investigate competition and opportunities influencing the companion diagnostics market from 2011 onwards
- You will see what will stimulate and restrain the companion diagnostics market from 2011
- You will discover the unmet needs in the market, driving the growth from 2011 onwards
- You will view expert opinion from our survey, including full interview transcripts.
1. EXECUTIVE SUMMARY
1.1 Companion Diagnostics Market Review
1.2 Aims, Scope and Format of the Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods
2. INTRODUCTION TO COMPANION DIAGNOSTICS
2.1 Changing Paradigms of Treatment
2.2 What is Personalised Medicine?
2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine
2.3.1 What are In Vitro Diagnostic (IVD) Tests?
2.3.2 How IVDs Help Provide Personalised Treatment
2.4 Companion Diagnostics: Tools for Personalised Medicine
2.4.1 Theranostics: A Subset of Companion Diagnostics
2.5 Biomarkers to Companion Diagnostics
2.5.1 Genomic Biomarkers
2.5.2 Genomic Biomarkers in Oncology
2.6 Development of Companion Diagnostics
3. THE WORLD COMPANION DIAGNOSTICS MARKET, 2010-2021
3.1 Scope and Limitations
3.2 Total Companion Diagnostics Market was Worth $1.30bn in 2010
3.3 Sales Forecast for Total Companion Diagnostics Market, 2010-2015
3.4 Sales Forecast for Total Companion Diagnostics Market, 2016-2021
3.5 Companion Diagnostics is One of the Fastest Growing Segments in the IVD Market
3.5.1 Companion Diagnostics Gaining Greater Share of the IVD Market
3.6 Theranostics Constituted 31.5% of the Companion Diagnostics Market in 2010
3.7 Strong Growth in the Theranostics Market, 2011-2021
3.7.1 Theranostics Gaining Greater Share of the Companion Diagnostics Market, 2011-2021
4. LEADING NATIONAL MARKETS FOR COMPANION DIAGNOSTICS, 2010-2021
4.1 Leading National Markets for Companion Diagnostics, 2010
4.2 Leading National Markets for Companion Diagnostics: Sales Forecast, 2011-2021
4.2.1 The US Companion Diagnostics Market, 2011-2021
4.2.2 The Leading European Companion Diagnostics Markets, 2011-2021
4.2.3 The Japanese Companion Diagnostics Market, 2011-2021
4.2.4 Emerging-Economy Companion Diagnostics Markets
4.2.4.1 The Chinese Companion Diagnostics Market, 2011-2021
4.2.4.2 The Indian Companion Diagnostics Market, 2011-2021
5. PRODUCTS IN THE COMPANION DIAGNOSTICS MARKET: MARKETED AND PIPELINE, 2011
5.1 Biomarkers Being Developed into Companion Diagnostics
5.2 Market for Companion Diagnostics: Small, but Growing
5.3 A Complex Market with Multiple Regulatory Pathways
5.4 Marketed Theranostics, 2011
5.5 Pipeline Companion Diagnostics
5.6 Oncology is the Leading Indication for the Development of Companion Diagnostics
6. COMPANION DIAGNOSTICS MARKET LANDSCAPE: COMPANIES AND PARTNERSHIPS, 2010-2011
6.1 Overview
6.2 Stakeholders in the Companion Diagnostics Market
6.2.1 Regulatory Authorities Promoting the Development of Companion Diagnostics
6.2.2 Testing Laboratories
6.2.3 Physicians and Patients: Need to be More Informed to Drive Treatment Decisions
6.2.4 The Market for Theranostic Products is Creating Opportunities for Pharmaceutical and Diagnostic Companies
6.3 Benefits of Employing Companion Diagnostics: Perspective of Pharmaceutical and Diagnostic Companies
6.4 Companies in the Companion Diagnostics Market
6.4.1 Factors Driving Companies to Enter the Companion Diagnostics Market
6.4.2 Companies in the Companion Diagnostics Market: Developing Products and Providing Services
6.5 Business Models for the Development of Companion Diagnostics
6.5.1 Few Pharmaceutical Companies Have Dedicated Diagnostics Units
6.5.2 Collaborating with Pharmaceuticals: A Win-Win for Diagnostic Companies
6.5.3 Roche: A One Stop Shop for Companion Diagnostics
6.5.4 Qiagen: Growing on the Partnership Model
6.6 Deals for Development of Companion Diagnostics, 2010-2011
7. SWOT ANALYSIS OF THE COMPANION DIAGNOSTICS MARKET
7.1 Introduction
7.2 Strengths and Weaknesses of the Sector
7.2.1 Maximising Benefits to Healthcare Stakeholders
7.2.2 Minimising Harm
7.2.3 Increasing Compliance
7.2.4 Streamlining Clinical Trials
7.2.5 Reviving Failed or Withdrawn Drugs
7.2.6 Reducing the Costs of Healthcare
7.2.7 Shifting From Reaction to Prevention
7.2.8 The Field of Diagnostics Has Traditionally Been an Undervalued Area of Science When Compared to the Production of Pharmaceuticals
7.2.9 Perceived Lower Revenues and Higher Marketing Costs
7.3 Opportunities and Threats
7.3.1 Biomarkers: Translating into Companion Diagnostics
7.3.2 Reimbursement Challenges
7.3.3 Lack of Clear Regulatory Guidelines on Companion Diagnostics
7.3.4 Complex Business Models: Contradicting Objectives
7.3.5 Threat to the Blockbuster Model of Pharmaceutical Companies
8. EXPERT OPINION
8.1 Director from a Diagnostics Company in the Sector (Views Provided Anonymously)
8.1.1 Most-Promising Therapeutic Areas for IVD
8.1.2 Unmet Medical Needs in IVD
8.1.3 Greatest Obstacles to Market Growth
8.1.4 Prospects for IVD Market Growth in Developing Countries
8.1.5 Prospects for Theranostics
8.2 Interview with Herbie Newell, Professor of Cancer Therapeutics, Northern Institute for Cancer Research, University of Newcastle, UK
8.2.1 The Importance of Biomarkers for Cancer Therapy
8.2.2 Technological Platforms Used in the Discovery of Novel Biomarkers
8.2.3 The Challenges of Translating Cancer Biomarker Discoveries to the Clinic
8.2.4 Cancer Heterogeneity and Targeted Therapy
8.2.5 Reform in Pharmaceutical R&D and the Importance of Public-Private Partnerships
8.2.6 Current Trends and the Future of Cancer Research
8.3 Vice President, Diagnostics Division of a Global Pharmaceutical Company (Views Provided Anonymously)
8.3.1 Definition of Companion Diagnostics
8.3.2 Pharmaceutical Company and Companion Diagnostics Market
8.3.3 Drivers and Restraints for Companion Diagnostics Market
8.3.4 Most Promising Therapeutic Areas for Development of Companion Diagnostic Tests
8.3.5 Recent Trends in the Companion Diagnostics Market and Future Growth
9. CONCLUSIONS
9.1 Overview
9.2 Prominent Companies in the Market
9.3 Commercial Drivers of the Companion Diagnostics Market
9.4 Pharmacogenomics: Driving the Personalised Medicine Approach
9.5 Personalised Medicine is a Strong Driver of the Theranostics Sector
9.6 Commercial Restraints in the Companion Diagnostics Market
9.7 Targeted Therapies Will Revolutionise the Current Model of Pharmaceutical R&D
9.8 Future Outlook and Concluding Remarks
Appendix A
Appendix B
Visiongain report evaluation form
1.1 Companion Diagnostics Market Review
1.2 Aims, Scope and Format of the Report
1.2.1 Chapter Outlines
1.3 Research and Analysis Methods
2. INTRODUCTION TO COMPANION DIAGNOSTICS
2.1 Changing Paradigms of Treatment
2.2 What is Personalised Medicine?
2.3 In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine
2.3.1 What are In Vitro Diagnostic (IVD) Tests?
2.3.2 How IVDs Help Provide Personalised Treatment
2.4 Companion Diagnostics: Tools for Personalised Medicine
2.4.1 Theranostics: A Subset of Companion Diagnostics
2.5 Biomarkers to Companion Diagnostics
2.5.1 Genomic Biomarkers
2.5.2 Genomic Biomarkers in Oncology
2.6 Development of Companion Diagnostics
3. THE WORLD COMPANION DIAGNOSTICS MARKET, 2010-2021
3.1 Scope and Limitations
3.2 Total Companion Diagnostics Market was Worth $1.30bn in 2010
3.3 Sales Forecast for Total Companion Diagnostics Market, 2010-2015
3.4 Sales Forecast for Total Companion Diagnostics Market, 2016-2021
3.5 Companion Diagnostics is One of the Fastest Growing Segments in the IVD Market
3.5.1 Companion Diagnostics Gaining Greater Share of the IVD Market
3.6 Theranostics Constituted 31.5% of the Companion Diagnostics Market in 2010
3.7 Strong Growth in the Theranostics Market, 2011-2021
3.7.1 Theranostics Gaining Greater Share of the Companion Diagnostics Market, 2011-2021
4. LEADING NATIONAL MARKETS FOR COMPANION DIAGNOSTICS, 2010-2021
4.1 Leading National Markets for Companion Diagnostics, 2010
4.2 Leading National Markets for Companion Diagnostics: Sales Forecast, 2011-2021
4.2.1 The US Companion Diagnostics Market, 2011-2021
4.2.2 The Leading European Companion Diagnostics Markets, 2011-2021
4.2.3 The Japanese Companion Diagnostics Market, 2011-2021
4.2.4 Emerging-Economy Companion Diagnostics Markets
4.2.4.1 The Chinese Companion Diagnostics Market, 2011-2021
4.2.4.2 The Indian Companion Diagnostics Market, 2011-2021
5. PRODUCTS IN THE COMPANION DIAGNOSTICS MARKET: MARKETED AND PIPELINE, 2011
5.1 Biomarkers Being Developed into Companion Diagnostics
5.2 Market for Companion Diagnostics: Small, but Growing
5.3 A Complex Market with Multiple Regulatory Pathways
5.4 Marketed Theranostics, 2011
5.5 Pipeline Companion Diagnostics
5.6 Oncology is the Leading Indication for the Development of Companion Diagnostics
6. COMPANION DIAGNOSTICS MARKET LANDSCAPE: COMPANIES AND PARTNERSHIPS, 2010-2011
6.1 Overview
6.2 Stakeholders in the Companion Diagnostics Market
6.2.1 Regulatory Authorities Promoting the Development of Companion Diagnostics
6.2.2 Testing Laboratories
6.2.3 Physicians and Patients: Need to be More Informed to Drive Treatment Decisions
6.2.4 The Market for Theranostic Products is Creating Opportunities for Pharmaceutical and Diagnostic Companies
6.3 Benefits of Employing Companion Diagnostics: Perspective of Pharmaceutical and Diagnostic Companies
6.4 Companies in the Companion Diagnostics Market
6.4.1 Factors Driving Companies to Enter the Companion Diagnostics Market
6.4.2 Companies in the Companion Diagnostics Market: Developing Products and Providing Services
6.5 Business Models for the Development of Companion Diagnostics
6.5.1 Few Pharmaceutical Companies Have Dedicated Diagnostics Units
6.5.2 Collaborating with Pharmaceuticals: A Win-Win for Diagnostic Companies
6.5.3 Roche: A One Stop Shop for Companion Diagnostics
6.5.4 Qiagen: Growing on the Partnership Model
6.6 Deals for Development of Companion Diagnostics, 2010-2011
7. SWOT ANALYSIS OF THE COMPANION DIAGNOSTICS MARKET
7.1 Introduction
7.2 Strengths and Weaknesses of the Sector
7.2.1 Maximising Benefits to Healthcare Stakeholders
7.2.2 Minimising Harm
7.2.3 Increasing Compliance
7.2.4 Streamlining Clinical Trials
7.2.5 Reviving Failed or Withdrawn Drugs
7.2.6 Reducing the Costs of Healthcare
7.2.7 Shifting From Reaction to Prevention
7.2.8 The Field of Diagnostics Has Traditionally Been an Undervalued Area of Science When Compared to the Production of Pharmaceuticals
7.2.9 Perceived Lower Revenues and Higher Marketing Costs
7.3 Opportunities and Threats
7.3.1 Biomarkers: Translating into Companion Diagnostics
7.3.2 Reimbursement Challenges
7.3.3 Lack of Clear Regulatory Guidelines on Companion Diagnostics
7.3.4 Complex Business Models: Contradicting Objectives
7.3.5 Threat to the Blockbuster Model of Pharmaceutical Companies
8. EXPERT OPINION
8.1 Director from a Diagnostics Company in the Sector (Views Provided Anonymously)
8.1.1 Most-Promising Therapeutic Areas for IVD
8.1.2 Unmet Medical Needs in IVD
8.1.3 Greatest Obstacles to Market Growth
8.1.4 Prospects for IVD Market Growth in Developing Countries
8.1.5 Prospects for Theranostics
8.2 Interview with Herbie Newell, Professor of Cancer Therapeutics, Northern Institute for Cancer Research, University of Newcastle, UK
8.2.1 The Importance of Biomarkers for Cancer Therapy
8.2.2 Technological Platforms Used in the Discovery of Novel Biomarkers
8.2.3 The Challenges of Translating Cancer Biomarker Discoveries to the Clinic
8.2.4 Cancer Heterogeneity and Targeted Therapy
8.2.5 Reform in Pharmaceutical R&D and the Importance of Public-Private Partnerships
8.2.6 Current Trends and the Future of Cancer Research
8.3 Vice President, Diagnostics Division of a Global Pharmaceutical Company (Views Provided Anonymously)
8.3.1 Definition of Companion Diagnostics
8.3.2 Pharmaceutical Company and Companion Diagnostics Market
8.3.3 Drivers and Restraints for Companion Diagnostics Market
8.3.4 Most Promising Therapeutic Areas for Development of Companion Diagnostic Tests
8.3.5 Recent Trends in the Companion Diagnostics Market and Future Growth
9. CONCLUSIONS
9.1 Overview
9.2 Prominent Companies in the Market
9.3 Commercial Drivers of the Companion Diagnostics Market
9.4 Pharmacogenomics: Driving the Personalised Medicine Approach
9.5 Personalised Medicine is a Strong Driver of the Theranostics Sector
9.6 Commercial Restraints in the Companion Diagnostics Market
9.7 Targeted Therapies Will Revolutionise the Current Model of Pharmaceutical R&D
9.8 Future Outlook and Concluding Remarks
Appendix A
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 2.1 Differences between Traditional & Personalised Medicine, 2011
Table 2.2 Examples of Clinically Relevant Cancer Biomarkers, 2011
Table 3.1 World Companion Diagnostics Market: Sales ($bn) and Market Share (%), 2010
Table 3.2 Total Companion Diagnostics Market: Sales Forecast ($bn), 2010-2021
Table 3.3 Market Shares (%) of Companion Diagnostics in the IVD Market, 2010, 2015 & 2021
Table 3.4 World Theranostics Market: Sales ($bn) and Market Share (%), 2010
Table 3.5 World Theranostics Market: Sales Forecast ($bn), 2010-2021
Table 3.6 Market Shares (%) of Theranostics in the Companion Diagnostics Market, 2010, 2015 & 2021
Table 4.1 Leading National Markets for Companion Diagnostics ($m), 2010
Table 4.2 Leading Companion Diagnostics National Market Forecasts ($m), 2010-2021
Table 4.3 Leading National Markets: Market Shares (%), 2010, 2015 & 2021
Table 4.4 The US Companion Diagnostics Market Forecast ($m), 2010-2021
Table 4.5 The EU5 Companion Diagnostics Market Forecasts ($m), 2010-2021
Table 4.6 The Japanese Companion Diagnostics Market Forecast ($m), 2010-2021
Table 4.7 The Chinese and Indian Companion Diagnostics Market Forecasts ($m), 2010-2021
Table 5.1 List of Biomarkers: Testing Required Prior to Prescription, 2011
Table 5.2 List of Biomarkers: Testing Recommended/For Information Only in Drug Label, FDA, 2011
Table 5.3 List of Some Marketed Theranostics, 2011
Table 5.4 Development Pipeline: Drug-Diagnostic Combinations, 2011
Table 6.1 Growth of Companion Diagnostics: Benefits for Pharmaceutical and Diagnostic Companies, 2011
Table 6.2 List of Some Companies in the Companion Diagnostics Market, 2011
Table 6.3 Qiagen Sales ($m), 2010
Table 6.4 Some Companion Diagnostic Deals, 2010
Table 6.5 Some Companion Diagnostic Deals, 2011
Table 7.1 SWOT Analysis of the Companion Diagnostics Market, 2011-2021
Table 7.2 Average Response Rates to Treatment for Various Diseases, 2010
Table 7.3 Drugs Metabolised by CYP450: 2C19 and 2D6, 2011
Table 9.1 Companion Diagnostics Market: World Sales Forecast ($bn), 2010, 2012, 2015, 2018, and 2021
Table 2.1 Differences between Traditional & Personalised Medicine, 2011
Table 2.2 Examples of Clinically Relevant Cancer Biomarkers, 2011
Table 3.1 World Companion Diagnostics Market: Sales ($bn) and Market Share (%), 2010
Table 3.2 Total Companion Diagnostics Market: Sales Forecast ($bn), 2010-2021
Table 3.3 Market Shares (%) of Companion Diagnostics in the IVD Market, 2010, 2015 & 2021
Table 3.4 World Theranostics Market: Sales ($bn) and Market Share (%), 2010
Table 3.5 World Theranostics Market: Sales Forecast ($bn), 2010-2021
Table 3.6 Market Shares (%) of Theranostics in the Companion Diagnostics Market, 2010, 2015 & 2021
Table 4.1 Leading National Markets for Companion Diagnostics ($m), 2010
Table 4.2 Leading Companion Diagnostics National Market Forecasts ($m), 2010-2021
Table 4.3 Leading National Markets: Market Shares (%), 2010, 2015 & 2021
Table 4.4 The US Companion Diagnostics Market Forecast ($m), 2010-2021
Table 4.5 The EU5 Companion Diagnostics Market Forecasts ($m), 2010-2021
Table 4.6 The Japanese Companion Diagnostics Market Forecast ($m), 2010-2021
Table 4.7 The Chinese and Indian Companion Diagnostics Market Forecasts ($m), 2010-2021
Table 5.1 List of Biomarkers: Testing Required Prior to Prescription, 2011
Table 5.2 List of Biomarkers: Testing Recommended/For Information Only in Drug Label, FDA, 2011
Table 5.3 List of Some Marketed Theranostics, 2011
Table 5.4 Development Pipeline: Drug-Diagnostic Combinations, 2011
Table 6.1 Growth of Companion Diagnostics: Benefits for Pharmaceutical and Diagnostic Companies, 2011
Table 6.2 List of Some Companies in the Companion Diagnostics Market, 2011
Table 6.3 Qiagen Sales ($m), 2010
Table 6.4 Some Companion Diagnostic Deals, 2010
Table 6.5 Some Companion Diagnostic Deals, 2011
Table 7.1 SWOT Analysis of the Companion Diagnostics Market, 2011-2021
Table 7.2 Average Response Rates to Treatment for Various Diseases, 2010
Table 7.3 Drugs Metabolised by CYP450: 2C19 and 2D6, 2011
Table 9.1 Companion Diagnostics Market: World Sales Forecast ($bn), 2010, 2012, 2015, 2018, and 2021
LIST OF FIGURES
Figure 2.1 The Pillars of Personalised Medicine
Figure 2.2 Type of Companion Diagnostics on the Basis of Purpose/Use, 2011
Figure 2.3 Development of Biomarkers into Companion Diagnostics, 2011
Figure 3.1 World Companion Diagnostics Market Share (%) in the IVD Market, 2010
Figure 3.2 World Companion Diagnostics Market: Sales Forecast ($bn), 2010-2021
Figure 3.3 World Companion Diagnostics Market Share (%) in the IVD Market, 2015
Figure 3.4 World Companion Diagnostics Market Share (%) in the IVD Market, 2021
Figure 3.5 World Theranostics Market Share (%) in the Companion Diagnostics Market, 2010
Figure 3.6 World Companion Diagnostics Sub-Markets: Sales Forecasts ($bn), 2010-2021
Figure 3.7 World Theranostics Market Share (%) in the Companion Diagnostics Market, 2015
Figure 3.8 World Theranostics Market Share (%) in the Companion Diagnostics Market, 2021
Figure 4.1 Companion Diagnostics Market Shares (%) in Leading National Markets, 2010
Figure 4.2 Companion Diagnostics Market Shares (%) in Leading National Markets, 2015
Figure 4.3 Companion Diagnostics Market Shares (%) in Leading National Markets, 2021
Figure 4.4 The US Companion Diagnostics Market Forecast ($m), 2010-2021
Figure 4.5 The EU5 Companion Diagnostics Market Forecasts ($m), 2010-2021
Figure 4.6 The Japanese Companion Diagnostics Market Forecast ($m), 2010-2021
Figure 4.7 The Chinese and Indian Companion Diagnostics Market Forecasts ($m), 2010-2021
Figure 6.1 Stakeholders in the Companion Diagnostics Market, 2011
Figure 6.2 Business Models for Development of Companion Diagnostics, 2011
Figure 7.1 Average Response Rates for Various Diseases, 2010
Figure 9.1 Companion Diagnostics Market: World Sales Forecast ($bn), 2010, 2012, 2015, 2018, and 2021
COMPANIES LISTED
20/20 Genesystems
Abbott Laboratories
Abbott Molecular
Abkine Pharmaceuticals
Advanced Cell Diagnostics
Aeterna Zentaris
Aetna
Agendia
Alacris Theranostics
Alere
Allegro Diagnostics
Almac Group
AltheaDx
Amgen
Amoy Diagnostics Company
Anthem
Ariad Pharmaceuticals
Array BioPharma
AssuerRx Health
AstraZeneca
Asuragen
Aureon Laboratories
AutoGenomics
Bayer Schering Pharma
Beckman Coulter
Biocartis
Biocrates Life Sciences
Biodesix
Biogen Idec
BioGenex Laboratories
BioMarin Pharmaceuticals
Biomarker Strategies
Biomedical Diagnostics (BMD)
bioMerieux
Biomonitor
Biotage
bioTheranostics
Boehringer Ingelheim
Brain Resource Company
Bristol-Myers Squibb
Cancer Research Technology Limited (CRT)
CancerGuide Diagnostics
Caprion Proteomics
Caris Life Sciences
Celera Corporation
Celgene Corporation
Centers for Medicare and Medicaid Services (CMS)
Cephalon
Cepheid
Cigna Corporation
Clavis Pharma
Clinical Reference Laboratory
Clovis Oncology
CompanDx
Crescendo Bioscience
Curidium Medica
Dako
Debiopharm Group
DiagnoCure
Dx assays
DxS
Eisai
Eli Lilly and Company
Endocyte
ERYtech Pharma
European Medicines Agency (EMA)
Exosome Diagnostics
Flagship Biosciences
Foundation Medicine
Genfit
GenMark Diagnostics
Genomic Health
Genzyme Genetics
GlaxoSmithKline
Hatteras Venture Partners
Health Net
HistologiX
Hoffmann-La Roche
Hologic
Humana
ImClone Systems
InDex Pharmaceuticals
Intersouth Partners
Inverness Medical Innovations
Invivoscribe Technologies
Ipsen
Ipsogen
Janssen Pharmaceutica
Johnson & Johnson
Kaiser Permanente
Kimball Genetics
Laboratory Corporation of America (LabCorp)
Laboratory for Personalized Molecular Medicine
Life Technologies Corporation
M.D. Anderson Cancer Center
MDxHealth
Merck KGaA
Merck Serono
MolecularMD
Monogram Biosciences
Myriad Genetics
Nanosphere
Neovacs
Newcastle University (UK)
Novartis Pharmaceuticals Corporation
Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
Oxford BioTherapeutics
Oxford Genome Sciences
Pfizer
Progenika Biopharma
Prometheus Laboratories
Psynova Neurotech
Qiagen
Quest Diagnostics
Quintiles Transnational Corporation
Randox Pharma Services
RiboMed Biotechnologies
Roche Molecular Systems
Rules-Based Medicine
Saladax Biomedical
Sanofi
Signal Genetics
Signature Diagnostics
Sirius Genomics
Skyline Diagnostics
Target Discovery
TcLand Expression
Telegraph Hill Partners
The Netherlands Cancer Institute (NKI)
Theranostics (NZ)
Theranostics Health
Third Wave Technologies
TIB MolBiol
Tragara Pharmaceuticals
Transgene
Transgenomic
TrimGen Corporation
Tufts Center for the Study of Drug Development
Unilabs
United HealthCare Services
US Food and Drug Administration (FDA)
US National Institutes of Health (NIH)
Ventana Medical Systems
Veridex
Weisenthal Cancer Group
WellPoint
Figure 2.1 The Pillars of Personalised Medicine
Figure 2.2 Type of Companion Diagnostics on the Basis of Purpose/Use, 2011
Figure 2.3 Development of Biomarkers into Companion Diagnostics, 2011
Figure 3.1 World Companion Diagnostics Market Share (%) in the IVD Market, 2010
Figure 3.2 World Companion Diagnostics Market: Sales Forecast ($bn), 2010-2021
Figure 3.3 World Companion Diagnostics Market Share (%) in the IVD Market, 2015
Figure 3.4 World Companion Diagnostics Market Share (%) in the IVD Market, 2021
Figure 3.5 World Theranostics Market Share (%) in the Companion Diagnostics Market, 2010
Figure 3.6 World Companion Diagnostics Sub-Markets: Sales Forecasts ($bn), 2010-2021
Figure 3.7 World Theranostics Market Share (%) in the Companion Diagnostics Market, 2015
Figure 3.8 World Theranostics Market Share (%) in the Companion Diagnostics Market, 2021
Figure 4.1 Companion Diagnostics Market Shares (%) in Leading National Markets, 2010
Figure 4.2 Companion Diagnostics Market Shares (%) in Leading National Markets, 2015
Figure 4.3 Companion Diagnostics Market Shares (%) in Leading National Markets, 2021
Figure 4.4 The US Companion Diagnostics Market Forecast ($m), 2010-2021
Figure 4.5 The EU5 Companion Diagnostics Market Forecasts ($m), 2010-2021
Figure 4.6 The Japanese Companion Diagnostics Market Forecast ($m), 2010-2021
Figure 4.7 The Chinese and Indian Companion Diagnostics Market Forecasts ($m), 2010-2021
Figure 6.1 Stakeholders in the Companion Diagnostics Market, 2011
Figure 6.2 Business Models for Development of Companion Diagnostics, 2011
Figure 7.1 Average Response Rates for Various Diseases, 2010
Figure 9.1 Companion Diagnostics Market: World Sales Forecast ($bn), 2010, 2012, 2015, 2018, and 2021
COMPANIES LISTED
20/20 Genesystems
Abbott Laboratories
Abbott Molecular
Abkine Pharmaceuticals
Advanced Cell Diagnostics
Aeterna Zentaris
Aetna
Agendia
Alacris Theranostics
Alere
Allegro Diagnostics
Almac Group
AltheaDx
Amgen
Amoy Diagnostics Company
Anthem
Ariad Pharmaceuticals
Array BioPharma
AssuerRx Health
AstraZeneca
Asuragen
Aureon Laboratories
AutoGenomics
Bayer Schering Pharma
Beckman Coulter
Biocartis
Biocrates Life Sciences
Biodesix
Biogen Idec
BioGenex Laboratories
BioMarin Pharmaceuticals
Biomarker Strategies
Biomedical Diagnostics (BMD)
bioMerieux
Biomonitor
Biotage
bioTheranostics
Boehringer Ingelheim
Brain Resource Company
Bristol-Myers Squibb
Cancer Research Technology Limited (CRT)
CancerGuide Diagnostics
Caprion Proteomics
Caris Life Sciences
Celera Corporation
Celgene Corporation
Centers for Medicare and Medicaid Services (CMS)
Cephalon
Cepheid
Cigna Corporation
Clavis Pharma
Clinical Reference Laboratory
Clovis Oncology
CompanDx
Crescendo Bioscience
Curidium Medica
Dako
Debiopharm Group
DiagnoCure
Dx assays
DxS
Eisai
Eli Lilly and Company
Endocyte
ERYtech Pharma
European Medicines Agency (EMA)
Exosome Diagnostics
Flagship Biosciences
Foundation Medicine
Genfit
GenMark Diagnostics
Genomic Health
Genzyme Genetics
GlaxoSmithKline
Hatteras Venture Partners
Health Net
HistologiX
Hoffmann-La Roche
Hologic
Humana
ImClone Systems
InDex Pharmaceuticals
Intersouth Partners
Inverness Medical Innovations
Invivoscribe Technologies
Ipsen
Ipsogen
Janssen Pharmaceutica
Johnson & Johnson
Kaiser Permanente
Kimball Genetics
Laboratory Corporation of America (LabCorp)
Laboratory for Personalized Molecular Medicine
Life Technologies Corporation
M.D. Anderson Cancer Center
MDxHealth
Merck KGaA
Merck Serono
MolecularMD
Monogram Biosciences
Myriad Genetics
Nanosphere
Neovacs
Newcastle University (UK)
Novartis Pharmaceuticals Corporation
Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)
Oxford BioTherapeutics
Oxford Genome Sciences
Pfizer
Progenika Biopharma
Prometheus Laboratories
Psynova Neurotech
Qiagen
Quest Diagnostics
Quintiles Transnational Corporation
Randox Pharma Services
RiboMed Biotechnologies
Roche Molecular Systems
Rules-Based Medicine
Saladax Biomedical
Sanofi
Signal Genetics
Signature Diagnostics
Sirius Genomics
Skyline Diagnostics
Target Discovery
TcLand Expression
Telegraph Hill Partners
The Netherlands Cancer Institute (NKI)
Theranostics (NZ)
Theranostics Health
Third Wave Technologies
TIB MolBiol
Tragara Pharmaceuticals
Transgene
Transgenomic
TrimGen Corporation
Tufts Center for the Study of Drug Development
Unilabs
United HealthCare Services
US Food and Drug Administration (FDA)
US National Institutes of Health (NIH)
Ventana Medical Systems
Veridex
Weisenthal Cancer Group
WellPoint
